Company to Pursue Broad Intellectual Property Strategy Related to Specific Cannabinoids to Establish Competitive Position through its Real Hemp Wholly-Owned Subsidiary
INDIANAPOLIS, IN - (http://www.financialnewsmedia.com News Alert) - Stevia Corp. (OTCQB: STEV) ("Stevia Corp" or the "Company"), an international farm management company and healthcare company focused on the commercial development of products that support a healthy lifestyle, including stevia and hemp and their compounds, is pleased to announce the filing of a second important provisional patent application with the United States Patent and Trademark Office for the treatment of pain using ibuprofen and Cannabidiol (CBD).
Ibuprofen is a non-steroidal drug that can be used to relieve pain and reduce fever. Ibuprofen is also widely recognized as a non-steroidal anti-inflammatory drug (NSAID). Like many NSAIDs, ibuprofen works by inhibiting the synthesis of prostaglandins which are fat-like molecules that are involved in mediating inflammation, pain and fever. It achieves this synthesis by inhibiting cyclooxygenase, an enzyme that is present in various tissues of the body. Ibuprofen is the active ingredient in popular OTC (over-the-counter) analgesics such as Advil® and Motrin®. For most pain sufferers, use of these drugs requires a long term, daily dosing regimen.
Cannabidiol (CBD) is a cannabinoid that is present in most varieties of the cannabis sativa and cannabis indica plants. Cannabinoids are unique to the cannabis sativa and cannabis indica plants. Unlike some of the other molecules found in varieties of the cannabis plant, it is non-psychoactive and it is not believed to have any addictive properties. It is also extremely well tolerated at high doses with little or no side effects. Cannabidiol catapulted into a national story after being an important part of the 2013 CNN documentary “Weed”.
George Blankenbaker, Stevia Corp commented, “This is our second key provisional patent application related to pain which is one of the largest healthcare markets in the world. In the past two weeks, we have announced our intention to secure patents and to launch products that contain specific cannabinoids in combination with either ibuprofen or acetaminophen. Ibuprofen and acetaminophen are two of the largest selling OTC drugs in the world and are the key ingredients behind Motrin® and Tylenol®.”
Mr. Blankenbaker continued, “As the market for both prescription and non-prescription pain reliever products continues to grow, unfortunately the amount of people experiencing side effects and the amount of people addicted to prescription pain killers also continues to grow. Our goal is to develop a painkiller that first and foremost works. Second, it must minimize adverse side effects. Finally, it must reduce the chance of addiction. We believe we will be able to develop these three attributes in a pain killer and as we stated in the previous announcement, we are exploring the possibility of partnering with a large pharmaceutical company that has extensive experience in the pain care market and particularly, experience with products that contain these two OTC medicines.”
A provisional patent application is not required to have a formal patent claim or an oath or declaration. However, an applicant who files a provisional patent must file a non-provisional patent with the United States Patent and Trademark Office within 12 months of the filing of the provisional patent application in order to benefit from the priority date. Most importantly, the provisional application allows the owner of the patent to market products that are believed to be covered by the patent application with “patent pending” status. Stevia Corp filed its application pursuant to other country’s patent statutes, which will allow Stevia Corp to claim the priority date in many other countries besides the United States upon the filing of a non-provisional patent application.
Tylenol is a registered trademark of Johnson and Johnson. Motrin is a registered trademark of McNeil Consumer Healthcare. Advil is a registered trademark of Pfizer.
About Stevia Corp. (OTCQB: STEV)
Stevia Corp. is a farm management company and healthcare company focused on developing highly nutritional, high value products through proprietary plant breeding, excellent agricultural methodologies and innovative post-harvest techniques. Stevia Corp invests in R&D and IP acquisition and manages its own propagation, nursery and plantations as well as provides services to contract growers and other industry growers. Stevia Corp was founded on the principal of implementing socially responsible, sustainable, quality agribusiness solutions to maximize the long-term efficient production of nutritional crops. For additional information please visit: www.steviacorp.us.
About the Hemp Industry Sector
Hemp is a crop that can be grown for food and non-food purposes. As a result of its numerous nutritional benefits, many new food products containing hemp seed and its oil are finding their way into the marketplace, including protein mixes, pasta, tortilla chips, salad dressings, snack products and frozen desserts. Non-dairy hemp "milk" beverages, which provide significant amounts of omega 3 essential fatty acids (EFAs) and protein, are also available. Hemp oil is also used in nutraceuticals and health care products as well as industrial applications.
As an industrial fiber source, hemp is undergoing rapid growth as a natural fiber in everything from clothing and textiles to automotive composites. The fiber is also gaining popularity as a building material such as insulation.
The Hemp Industries Association (HIA) estimated that the 2013 retail sales value of hemp food and body care products in the United States was $184 million. When clothing, paper, auto parts, building materials and various other products are included, the HIA estimates that the total retail value of hemp products sold in the US in 2013 to be at least $581 million and included more than 50,000 products.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, development of a product containing both ibuprofen and cannabidiol, development of a product containing both acetaminophen and cannabidiol, potential joint venture for future product development, potential of CBD for treating diseases, annual retail value of hemp products sold in the U.S., growth of industrial hemp product industry, product development and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Stevia Corp. Investor Relations
Source: Stevia Corp.
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated one thousand five hundred dollars for Stevia Corp news coverage by a non-affiliated third party. FNMG HOLDS NO SHARES OF Stevia Corp.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.